SLS Stock Gains Amid JPMorgan, Stifel Stake Increases
Sellas Group (NASDAQ: SLS) shares saw increased institutional interest with JPMorgan opening a new stake and Stifel boosting its holdings. This activity precedes key data from its AML trials, potentially influencing future market perception. The company is advancing its Phase 2 and Phase 3 trials for acute myeloid leukemia (AML) treatments, with anticipated data releases that could shape its development trajectory.
* Watch as institutional investors like JPMorgan and Stifel increase their positions ahead of anticipated clinical trial data.